Streetbeat News

Price Targets

ITCI

Morgan Stanley analyst Jeffrey Hung has reiterated an Overweight rating on Intra-Cellular Therapies (NASDAQ:ITCI) and maintained a price target of $80.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 1:18 pm

C

CRBG

Citigroup analyst Michael Ward has reinstated Corebridge Financial (NYSE:CRBG) with a Neutral rating and announced a $19 price target.

Portfolio Pulse from richadhand@benzinga.com

July 11, 2023 | 1:17 pm

IMCR

Morgan Stanley analyst Andrew Galler has reiterated an Overweight rating on Immunocore Hldgs (NASDAQ:IMCR) and maintained a $79 price target.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 1:16 pm

GILD

Morgan Stanley analyst Matthew Harrison has reiterated an Equal-Weight rating on Gilead Sciences (NASDAQ:GILD) and maintained a price target of $86.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 1:14 pm

HLMN

Canaccord Genuity analyst Brian McNamara has initiated coverage on Hillman Solns (NASDAQ:HLMN) with a Buy rating and a price target of $12.

Portfolio Pulse from richadhand@benzinga.com

July 11, 2023 | 1:13 pm

FMC

Morgan Stanley analyst Vincent Andrews has maintained an Overweight rating on FMC (NYSE:FMC) but lowered the price target from $145 to $110.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 1:12 pm

ETRN

Morgan Stanley analyst Devin McDermott has reiterated an Overweight rating on Equitrans Midstream (NYSE:ETRN) and maintained a $14 price target.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 1:11 pm

EQH

Morgan Stanley analyst Nigel Dally has reiterated an Overweight rating on Equitable Hldgs (NYSE:EQH) and maintained a $40 price target.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 1:09 pm

ENLC

Morgan Stanley analyst Robert Kad has reiterated an Overweight rating on EnLink Midstream (NYSE:ENLC) and maintained a $17 price target.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 1:08 pm

LLY

Morgan Stanley analyst David Phung has maintained an 'Overweight' rating on Eli Lilly (NYSE:LLY) and raised the price target from $507 to $551.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 1:06 pm